We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.61%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$22.7M
Cap. Flow
-$16.4M
Cap. Flow %
-3.26%
Top 10 Hldgs %
48.75%
Holding
84
New
17
Increased
18
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$38.4M
2
ISRG icon
Intuitive Surgical
ISRG
+$14.2M
3
RGEN icon
Repligen
RGEN
+$13.6M
4
GMAB icon
Genmab
GMAB
+$13.3M
5
HNGE
Hinge Health
HNGE
+$13M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
2
HUM icon
Humana
HUM
+$13.3M
3
GKOS icon
Glaukos
GKOS
+$13.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.93M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
76
NewAmsterdam Pharma
NAMS
$3.54B
– –
-68,000
Closed -$1.39M
NBIX icon
77
Neurocrine Biosciences
NBIX
$17.7B
– –
-85,700
Closed -$9.48M
PCVX icon
78
Vaxcyte
PCVX
$8.02B
– –
-23,000
Closed -$868K
REGN icon
79
Regeneron Pharmaceuticals
REGN
$70.5B
– –
-25,400
Closed -$16.1M
RGNX icon
80
Regenxbio
RGNX
$631M
– –
-260,000
Closed -$1.86M
RPRX icon
81
Royalty Pharma
RPRX
$26.1B
– –
-87,000
Closed -$2.71M
UTHR icon
82
United Therapeutics
UTHR
$26.4B
– –
-16,800
Closed -$5.18M
VERA icon
83
Vera Therapeutics
VERA
$2.55B
– –
-91,000
Closed -$2.19M
XBI icon
84
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-94,000
Closed -$7.62M
1 2 3
4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q2 2025 Portfolio in Review

As of Q2 2025, Avidity Partners Management held 84 positions worth $502M, down 4.3% from $525M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Avidity Partners Management withdrew a net $16.4M in Q2 2025, closing 28 positions and reducing 14 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 91% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Jade Biosciences worth $11.3M.

  • Avidity Partners Management's largest Q2 2025 buy was Jade Biosciences: 1,127,186 shares worth $11.3M.
  • Avidity Partners Management added most to CG Oncology in Q2 2025, an estimated $12.5M increase.
  • Avidity Partners Management's biggest Q2 2025 reduction was Humana, cutting an estimated $13.3M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q2 2025, selling an estimated $16.1M.
  • Avidity Partners Management's ten largest holdings make up 49% of its $502M portfolio in Q2 2025.
  • Avidity Partners Management opened 17 new positions and closed 28 in Q2 2025.
  • Avidity Partners Management's portfolio value fell 4.3% quarter-over-quarter to $502M.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.